HyperArc multiple brain metastases report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20240228Keywords:
HyperArc, RTOG quality indices, Brain metastases, Stereotactic radiosurgeryAbstract
This report presents the initial clinical experience with HyperArc, a novel modality that incorporates a non-coplanar, arc-based multileaf collimator (MLC) and automated treatment optimization and dose delivery. The study focuses on a patient who had previously received whole-brain radiotherapy. The effectiveness and challenges of HyperArc were assessed by evaluating various quality indices for stereotactic radiosurgery within the RTOG protocol, as well as an additional measure of toxicity in the form of the V12Gy volume. The HyperArc plan achieved quality indices of 1.13, 4.58, and 0.88 for CI, GI, and CIPaddick, respectively. The mean ICRU83 value was 0.17±0.01, and it remained consistent across all six lesions. The V12Gy value was equal to 8.76 cc. The HyperArc plan successfully met the constraints for organs-at-risk (OAR). These results suggest that HyperArc is a suitable modality for treating multiple brain metastases, as indicated by the quality indices and metrics. Additionally, V12Gy is a valuable indicator for assessing low-dose spillage.
References
Patchell RA. The Management of Brain Metastases. Cancer Treat Rev. 2003;29(6):533-40.
Ohira S, Ueda Y, Akino Y, Hashimoto M, Masaoka A, Hirata T, et al. HyperArc VMAT planning for single and multiple brain metastases stereotactic radiosurgery: a new treatment planning approach. Radiat Oncol. 2018;13(1):13.
Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, et al. Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys. 1993;27(5):1231-9.
Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93(3):219-22.
Paddick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index. J Neurosurg. 2006;105:194-201.
ICRU. Report 83: Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). J ICRU. 2010;10(1):1-106.
Miften M, Olch A, Mihailidis D, Moran J, Pawlicki T, Molineu A, et al. Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218. Med Phys. 2018;45(4):e53-e83.
Ohira S, Ueda Y, Akino Y, Hashimoto M, Masaoka A, Hirata T, et al. HyperArc VMAT planning for single and multiple brain metastases stereotactic radiosurgery: a new treatment planning approach. Radiat Oncol. 2018;13(1):13.
Simon M, Papp J, Csiki E, Kovács Á. Plan Quality Assessment of Fractionated Stereotactic Radiotherapy Treatment Plans in Patients With Brain Metastases. Front Oncol. 2022;12:846609.
Ruggieri R, Naccarato S, Mazzola R, Ricchetti F, Corradini S, Fiorentino A, et al. Linac-Based Radiosurgery for Multiple Brain Metastases: Comparison Between Two Mono-Isocenter Techniques with Multiple Non-Coplanar Arcs. Radiother Oncol. 2019;132:70-8.
Hsu SM, Lai YC, Jeng CC, Tseng CY. Dosimetric Comparison of Different Treatment Modalities for Stereotactic Radiotherapy. Radiat Oncol. 2017;12(1):1-11.
Paddick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index. J Neurosurg. 2006;105:194-201.
Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD. The radiosurgery fractionation quandary: single fraction or hypofractionation? Neuro Oncol. 2017;19(2):38-49.
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078-101.
Gloi AM. Feasibility of MPC enhanced couch as SRS/SBRT Pretreatment QA. Int J Sci Res Updates. 2023;6(2):1-16.
